当前位置: 首页 >> 检索结果
281. Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis.
作者: Xiang Guo.;Brandon W Higgs.;Anne-Christine Bay-Jensen.;Yuling Wu.;Morten A Karsdal.;Michael Kuziora.;Alex Godwood.;David Close.;Patricia C Ryan.;Lorin K Roskos.;Wendy I White.
来源: Rheumatology (Oxford). 2018年57卷1期175-184页
Targeting the granulocyte-macrophage colony-stimulating factor (GM-CSF) pathway holds great potential in the treatment of inflammatory diseases. Mavrilimumab, a human monoclonal GM-CSF receptor-α antibody, has demonstrated clinical efficacy in RA. Our current study aimed to elucidate mechanisms of action and identify peripheral biomarkers associated with therapeutic responses of GM-CSF antagonism in RA.
282. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study.
作者: Anne-Kathrin Tausche.;Rieke Alten.;Nicola Dalbeth.;Jeff Kopicko.;Maple Fung.;Scott Adler.;Nihar Bhakta.;Chris Storgard.;Scott Baumgartner.;Kenneth Saag.
来源: Rheumatology (Oxford). 2017年56卷12期2170-2178页
To investigate the efficacy and safety of lesinurad, a selective uric acid reabsorption inhibitor, in a 6 month, phase 3 clinical trial and extension study.
283. Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy.
作者: Xavier M Teitsma.;Johannes W G Jacobs.;Paco M J Welsing.;Attila Pethö-Schramm.;Michelle E A Borm.;Lidy Hendriks.;Natasja H A M Denissen.;Jacob M van Laar.;Floris P J G Lafeber.;Johannes W J Bijlsma.
来源: Rheumatology (Oxford). 2017年56卷12期2179-2189页
To evaluate the effect of initiation of tocilizumab, with or without MTX, compared with MTX alone on patient-reported outcomes (PROs), in DMARD-naïve patients with early RA.
284. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?
作者: Fowzia Ibrahim.;Beatriz Lorente-Cánovas.;Caroline J Doré.;Ailsa Bosworth.;Margaret H Ma.;James B Galloway.;Andrew P Cope.;Ira Pande.;David Walker.;David L Scott.
来源: Rheumatology (Oxford). 2017年56卷11期2004-2014页
RA patients receiving TNF inhibitors (TNFi) usually maintain their initial doses. The aim of the Optimizing Treatment with Tumour Necrosis Factor Inhibitors in Rheumatoid Arthritis trial was to evaluate whether tapering TNFi doses causes loss of clinical response.
285. 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.
作者: Paul Emery.;Jirí Vencovský.;Anna Sylwestrzak.;Piotr Leszczynski.;Wieslawa Porawska.;Asta Baranauskaite.;Vira Tseluyko.;Vyacheslav M Zhdan.;Barbara Stasiuk.;Roma Milasiene.;Aaron Alejandro Barrera Rodriguez.;Soo Yeon Cheong.;Jeehoon Ghil.
来源: Rheumatology (Oxford). 2017年56卷12期2093-2101页
To compare the 52-week efficacy and safety of SB4 [an etanercept biosimilar] with reference etanercept (ETN) in patients with active RA.
286. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.
作者: Iain B McInnes.;Philip J Mease.;Christopher T Ritchlin.;Proton Rahman.;Alice B Gottlieb.;Bruce Kirkham.;Radhika Kajekar.;Eumorphia-Maria Delicha.;Luminita Pricop.;Shephard Mpofu.
来源: Rheumatology (Oxford). 2017年56卷11期1993-2003页
To assess long-term efficacy, safety and tolerability of secukinumab up to 104 weeks in patients with active PsA.
287. Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.
作者: Josef S Smolen.;Jung-Yoon Choe.;Nenad Prodanovic.;Jaroslaw Niebrzydowski.;Ivan Staykov.;Eva Dokoupilova.;Asta Baranauskaite.;Roman Yatsyshyn.;Mevludin Mekic.;Wieskawa Porawska.;Hana Ciferska.;Krystyna Jedrychowicz-Rosiak.;Agnieszka Zielinska.;Jasmine Choi.;Young Hee Rho.
来源: Rheumatology (Oxford). 2017年56卷10期1771-1779页
SB2 is a biosimilar to the reference infliximab (INF). Similar efficacy, safety and immunogenicity between SB2 and INF up to 30 weeks were previously reported. This report investigates such clinical similarity up to 54 weeks, including structural joint damage.
288. Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy.
作者: Sytske Anne Bergstra.;Robert B M Landewé.;Tom W J Huizinga.;Cornelia F Allaart.
来源: Rheumatology (Oxford). 2017年56卷10期1721-1728页
To compare 10-year disease outcomes of RA patients who have continuous low disease activity and are on MTX with or without initial combination therapy with infliximab or prednisone and SSZ.
289. Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial.
作者: Nicole P C Konijn.;Lilian H D van Tuyl.;Maarten Boers.;Debby den Uyl.;Marieke M Ter Wee.;Lindsey K M van der Wijden.;Irene E M Bultink.;Pit J S M Kerstens.;Alexandre E Voskuyl.;Dirkjan van Schaardenburg.;Michael T Nurmohamed.;Willem F Lems.
来源: Rheumatology (Oxford). 2017年56卷9期1586-1596页
To assess the efficacy and safety of initial COBRA-light vs COBRA therapy in RA patients after a 4-year follow-up period.
290. Limited value for ultrasonography in predicting flare in rheumatoid arthritis patients with low disease activity stopping TNF inhibitors.
作者: Femke B Lamers-Karnebeek.;Jolanda J Luime.;David F Ten Cate.;Steven Teerenstra.;Nanno W A A Swen.;Andreas H Gerards.;Jos Hendrikx.;Emma M van Rooyen.;Ramon Voorneman.;Cees Haagsma.;Natalja Basoski.;Mike de Jager.;Marjan Ghiti Moghadam.;Monique N Efde.;Yvonne P M Goekoop-Ruiterman.;Piet L C M van Riel.;Johannes W G Jacobs.;Tim L Jansen.
来源: Rheumatology (Oxford). 2017年56卷9期1560-1565页
Ultrasonography (US) can be used for treatment decisions in RA patients. This study investigated the added value of US to clinical variables in predicting flare in RA patients with longstanding low disease activity when stopping TNF inhibitors (TNFi).
291. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
作者: Désirée van der Heijde.;Maxime Dougados.;Robert Landewé.;Joachim Sieper.;Walter P Maksymowych.;Martin Rudwaleit.;Filip Van den Bosch.;Jürgen Braun.;Philip J Mease.;Alan J Kivitz.;Jessica Walsh.;Owen Davies.;Lars Bauer.;Bengt Hoepken.;Luke Peterson.;Atul Deodhar.
来源: Rheumatology (Oxford). 2017年56卷9期1498-1509页
The aim was to assess the long-term safety and efficacy of certolizumab pegol over 4 years of continuous treatment in patients with axial spondyloarthritis (axSpA), including both AS and non-radiographic (nr-) axSpA.
292. Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials.
作者: Regina Rendas-Baum.;Mark Kosinski.;Amitabh Singh.;Charles A Mebus.;Bethany E Wilkinson.;Gene V Wallenstein.
来源: Rheumatology (Oxford). 2017年56卷8期1386-1394页
RA causes high disability levels and reduces health-related quality of life, triggering increased costs and risk of unemployment. Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. These post hoc analyses of phase 3 data aimed to assess monthly medical expenditure (MME) and risk of job loss for tofacitinib treatment vs placebo.
293. Long-term effects of a lifestyle intervention and oral glucosamine sulphate in primary care on incident knee OA in overweight women.
作者: Bastiaan C de Vos.;Marieke L A Landsmeer.;Marienke van Middelkoop.;Edwin H G Oei.;Marjolein Krul.;Sita M A Bierma-Zeinstra.;Jos Runhaar.
来源: Rheumatology (Oxford). 2017年56卷8期1326-1334页
The present study was designed to evaluate the effect of a lifestyle intervention aimed to reduce body weight and of oral glucosamine sulphate on the incidence of knee osteoarthritis (OA) after 6-7 years in a population of middle-aged, overweight women, without knee OA at baseline.
294. Non-radiographic axial spondyloarthritis patients without initial evidence of inflammation may develop objective inflammation over time.
作者: Xenofon Baraliakos.;Joachim Sieper.;Su Chen.;Aileen L Pangan.;Jaclyn K Anderson.
来源: Rheumatology (Oxford). 2017年56卷7期1162-1166页
In patients with active axial spondyloarthritis (axSpA), inflammation in the SIJ or spine on MRI, an elevated CRP level or both are considered useful objective assessments for disease activity and initiation of TNF antagonists. The aim of this post hoc analysis of the randomized, double-blind ABILITY-1 study (NCT00939003) was to assess changes in objective inflammation over time.
295. Bone curvature changes can predict the impact of treatment on cartilage volume loss in knee osteoarthritis: data from a 2-year clinical trial.
作者: Jean-Pierre Raynauld.;Jean-Pierre Pelletier.;Philippe Delorme.;Pierre Dodin.;François Abram.;Johanne Martel-Pelletier.
来源: Rheumatology (Oxford). 2017年56卷6期989-998页
Knee bone curvature assessed by MRI was associated with OA cartilage loss. A recent knee OA trial demonstrated the superiority of chondroitin sulfate over celecoxib (comparator) at reducing cartilage volume loss (CVL) in the medial compartment (condyle). The main objectives were to identify which baseline bone curvature regions of interest (BCROI) best associated with CVL and investigate whether baseline BCROI and 2-year change are correlated with the protective effect of chondroitin sulphate on CVL.
296. Chronic nasal Staphylococcus aureus carriage identifies a subset of newly diagnosed granulomatosis with polyangiitis patients with high relapse rate.
作者: Anna Salmela.;Niels Rasmussen.;Jan Willem Cohen Tervaert.;David R W Jayne.;Agneta Ekstrand.; .
来源: Rheumatology (Oxford). 2017年56卷6期965-972页
The aim of this study was to evaluate whether chronic nasal carriage of Staphylococcus aureus (SA) is related to relapses in patients with newly diagnosed ANCA-associated vasculitis (AAV).
297. A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes.
作者: Chantal A M Bouman.;Aatke van der Maas.;Noortje van Herwaarden.;Eric H Sasso.;Frank H J van den Hoogen.;Alfons A den Broeder.
来源: Rheumatology (Oxford). 2017年56卷6期973-980页
The aim was to evaluate the predictive value of the baseline multi-biomarker disease activity (MBDA) score in long-standing RA patients with low disease activity tapering TNF inhibitors (TNFi) for successful tapering or discontinuation, occurrence of flare and major flare, and radiographic progression.
298. The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) study.
作者: Otylia Kowal-Bielecka.;Sylwia Chwiesko-Minarowska.;Pawel L Bernatowicz.;Yannick Allanore.;Timothy Radstake.;Marco Matucci-Cerinic.;Jasper Broen.;Roger Hesselstrand.;Dorota Krasowska.;Gabriella Riemekasten.;Madelon Vonk.;Oksana Kowalczuk.;Marek Bielecki.;Robert Milewski.;Lech Chyczewski.;Jacek Niklinski.;Krzysztof Kowal.
来源: Rheumatology (Oxford). 2017年56卷5期844-852页
The arachidonate 5-lipoxygenase activating protein (ALOX5AP) regulates synthesis of leukotrienes (LTs), which are important mediators of inflammation and connective tissue remodelling. The aim of this study was to evaluate if single nucleotide polymorphisms (SNPs) of ALOX5AP confer risk of SSc and/or SSc-related organ involvement.
299. Work disability in non-radiographic axial spondyloarthritis patients before and after start of anti-TNF therapy: a population-based regional cohort study from southern Sweden.
作者: Johan K Wallman.;Anna Jöud.;Tor Olofsson.;Lennart T H Jacobsson.;Henning Bliddal.;Lars E Kristensen.
来源: Rheumatology (Oxford). 2017年56卷5期716-724页
The aim was to assess work-loss days before and after commencement of anti-TNF treatment in patients with non-radiographic axial spondylarthritis (nr-axSpA).
300. Clinical associations with venous thromboembolism in anti-neutrophil cytoplasm antibody-associated vasculitides.
作者: Andreas Kronbichler.;Johannes Leierer.;Gisela Leierer.;Gert Mayer.;Alina Casian.;Peter Höglund.;Kerstin Westman.;David Jayne.; .
来源: Rheumatology (Oxford). 2017年56卷5期704-708页
To assess potential associations for the development of venous thromboembolic events in patients with ANCA-associated vasculitides (AAV).
|